Scots firm and uni to play leading role in Oz medical trials

Glasgow-based health app developer MindMate is partnering with an Australian biotechnology company that is developing treatments for Alzheimer's and other age-related neurodegenerative disorders.

Patrick Renner, Susanne Mitschke and Rogelio Arellano of MindMate. Picture: Stewart Attwood

The partnership will see Actinogen Medical use MindMate’s cognitive health software to recruit patients for a pioneering trial, to prove the effectiveness of a drug in patients with Alzheimer’s.

MindMate has integrated with Actinogen’s clinical trial and will support patient recruitment in the US, UK and Australia.

Sign up to our daily newsletter

The i newsletter cut through the noise

The University of Edinburgh is one of Actinogen’s partner sites for the “XanADu” trial.

Susanne Mitschke, MindMate’s chief executive and co-founder, said: “This partnership is a fantastic opportunity to collaborate with one of the leading research organisations in Scotland and shows that Scotland is continuing to drive innovation also through world-leading biotech developments.”

MindMate is a free cognitive health and lifestyle app used by more than one million people worldwide.